MedTrace Logo

Duration of Postop Analgesia After Inguinal Hernia Surgery Treated with TAP Block Vs II/IH Nerve Block

NCT06812741 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-02-28

No results posted yet for this study

Summary

Comparing Postop Analgesia after Inguinal Hernia Surgery treated with TAP Block Vs Ilioinguinal/ Iliohypogastric Nerve Block

Conditions

  • Postoperative Analgesia

Interventions

DRUG

Transversus abdominis plane (TAP) block with 0.25 % bupivacaine

The probe was placed in a plane transverse to the lateral abdominal wall in the mid-axillary line immediately cephalad to the iliac crest. The needle was advanced immediately anterior to the probe using the in-plane needle-probe orientation and advanced posteriorly until the needle was observed to penetrate the interface between the internal oblique and transversus abdominis muscles. Thereafter, a local anesthetic (0.2 mL/kg of 0.25 % bupivacaine) was injected incrementally, and the spread was observed within the plane.

DRUG

Ilioinguinal/iliohypogastric Nerve Block with 0.25 % bupivacaine

The ultrasound probe was placed immediately medial and slightly cephalad to the upper aspect of the anterior superior iliac spine to obtain a short-axis view of the nerves situated between the two abdominal muscles (internal oblique and transversus abdominis), A 22 G needle tip \~1 cm caudal to the probe surface was introduced and was advanced until a characteristic 'tenting' of the interface between the two muscles was seen and was then further advanced deep to this interface until a pop was felt and then the injectate (0.2 mL/kg of 0.25 % bupivacaine) was observed spreading between these two layers.

Sponsors & Collaborators

  • Pakistan Navy Station Shifa Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-09
Primary Completion
2024-07-28
Completion
2024-07-28

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06812741 on ClinicalTrials.gov